LMAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
LeMaitre Vascular Inc (LMAT) is currently not a strong buy for a beginner investor with a long-term strategy. While the company has shown strong financial performance in its latest quarter, the technical indicators suggest the stock is overbought, and hedge funds are significantly selling. Additionally, the stock's short-term trend indicates potential downside in the coming weeks. Given the lack of positive trading signals and no recent news catalysts, it is better to hold off on buying this stock at the current pre-market price.
The stock is showing bullish momentum with a positive MACD histogram (0.456) and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the RSI_6 is at 80.355, indicating the stock is overbought. Key resistance levels are at R1: 91.021 and R2: 92.563, while support levels are at S1: 86.028 and S2: 84.486.
Strong financial performance in Q3 2025: Revenue increased by 11.36% YoY, Net Income up 55.84% YoY, EPS up 44.90% YoY, and Gross Margin improved to 75.28%.
Hedge funds are selling heavily, with a 398.42% increase in selling activity over the last quarter. The stock is overbought based on RSI, and short-term trends suggest potential downside (-1.02% in the next week, -3.43% in the next month). No recent news or congress trading data to support a positive sentiment.
In Q3 2025, LeMaitre Vascular Inc reported strong growth: Revenue increased to $61.046M (up 11.36% YoY), Net Income rose to $17.362M (up 55.84% YoY), EPS improved to $0.71 (up 44.90% YoY), and Gross Margin increased to 75.28% (up 11.00% YoY).
No recent analyst rating or price target changes available.
